Document resource
Objectives Systemic lupus erythematosus (SLE) remains a disease of high unmet medical need. Protean manifestations and the lack of clear understanding of etiology, pathogenesis, and disease subgroups hinder the development and application of targeted therapeutic approaches. Community-wide access to a longitudinal, highly curated, centralized patient dataset with linked biospecimens and molecular data is critical to enable advances in this area. The Lupus Nexus (LNx) is a lupus registry, biorepository, and data exchange platform that addresses this need.Methods To ensure that the design of LNx reflected the needs of the research and patient communities, LNx was developed with guidance from over 100 individuals, representing clinicians and scientists from academia and industry, governmental and non-profit groups, and individuals living with lupus.The LNx includes a prospective, longitudinal observational study, the Lupus Landmark Study, that is currently enrolling up to 3,500 participants into four cohorts: new-onset, active lupus nephritis, extra-renal flare, and prevalent SLE. The clinical data include parameters such as patient- and clinician-reported outcomes (PRO and CLINRO), full medical history, social history and determinants of health, and environmental exposures, among others. Linked biospecimens include PBMCs, DNA, RNA, urine, plasma, serum, saliva, stool, and tissue. The LNx Data Repository, Exchange, and Analytics platforM (DREAM) houses all LNx data and provides portals for both researchers and patients to access the resource. Specific analyses, such as genomics, transcriptomics, and proteomics, are underway to seed the DREAM and stimulate broader community utilization of LNx. Importantly, since all raw data from the biospecimen analyses will be deposited in DREAM, it will amass a deep and comprehensive dataset over time.Results As of October 2025, there are over 570 enrolled participants. Over 10,000 unique samples (participant x timepoint x sample type) have been collected. The registry is reflective of the population affected by lupus with 40% Black, 39% White, 12% Asian/Pacific Islander, and 16% Hispanic patients.Conclusions LNx is the first of its kind collaborative, patient-centric, lupus research platform poised to become the leading source of prospective, longitudinally well-phenotyped, comprehensive data with linked biospecimens and analyzed biosample data available to the entire research community.